Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours

Figure 1 Overall survival. The graphs present an overview of the long-term survival of the entire study cohort based on tumour (A) and nodal (B) stages.

Figure 2 Impact of American Joint Committee on Cancer/Union for International Cancer Control stage on survival of patients with or without neoadjuvant pretreatment. The graphs show the long-term survival of patients with or without neoadjuvant pretreatment and with the same postoperative UICC stage. Tx: treatment; UICC: Union for International Cancer Control.

Figure 3 Impact of tumour stage on survival of patients with or without neoadjuvant pretreatment. The graphs present the long-term survival of patients with or without neoadjuvant pretreatment and with similar postoperative tumour stages (early stage cancers: pT1/2; advanced stage cancers: pT3/4). Tx: Treatment.

Figure 4 Impact of nodal stage on survival of patients with or without neoadjuvant pretreatment. The graphs show the long-term survival of patients with or without neoadjuvant pretreatment and with the same postoperative nodal stages (pN0/pN1/pN2/pN3). Tx: Treatment.

Figure 5 Impact of T and N down-staging on outcome after neoadjuvant treatment. A: The long-term survival of patients with either T “down-staging” or “unchanged/up-staging” after neoadjuvant treatment; B: The long-term survival of patients with either N “down-staging” or “unchanged/up-staging” after neoadjuvant treatment. N: Nodal; T: Tumour; Tx: Treatment.